Valuation: Pliant Therapeutics, Inc.

Market Cap 53.48M 47.75M 44.12M 39.98M 74.79M 5.08B 76.03M 531M 210M 2.66B 201M 196M 8.39B P/E 2026 *
-0.6x
P/E 2027 * -0.65x
Enterprise Value -64.57M -57.66M -53.27M -48.27M -90.31M -6.13B -91.8M -641M -254M -3.21B -242M -237M -10.12B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.77%
Yield 2026 *
-
Yield 2027 * -
10-20 Pliant Therapeutics, Inc. Announces Appointment of Craig Blanchette, Ph.D. as Senior Vice President, Research CI
10-19 Pliant Therapeutics, Inc. Announces Presentation At European Society For Medical Oncology Congress 2026 Featuring FORTIFY Phase 1b Indication Expansion Trial Of PLN-101095 CI
09-30 Pliant Therapeutics Appoints David Raben as Chief Medical Officer MT
09-30 Pliant Therapeutics, Inc. Announces Appointment of David Raben, M.D., as Chief Medical Officer CI
09-20 Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from S&P Global BMI Index CI
08-18 Pliant Therapeutics, Inc. Receives FDA Fast Track Designation For PLN-101095 In Combination With Pembrolizumab For Treatment Of ICI-Refractory Solid Tumors CI
08-11 Pliant Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-13 Pliant Therapeutics, Inc. Appoints Flavia Borellini and Robert Iannone to Its Board of Directors CI
05-22 Pliant Therapeutics, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2026, May-19-2026 11:30 AM
05-11 Pliant Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-30 Pliant Therapeutics Announces First Patient Dosed in Fortify Phase 1B Indication Expansion Trial Evaluating Pln-101095 in Patients with Ici-Refractory Solid Tumors CI
04-18 Pliant Therapeutics Announces Updated Data from Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors CI
04-18 Pliant Therapeutics says PLN-101095 generally well tolerated; most common TRAE was rash, one grade 3 TRAE observed RE
1 day-0.20%
1 week-4.03%
Current month-20.04%
1 month-24.25%
3 months-20.77%
6 months-30.35%
Current year-29.21%
1 week 0.83
Extreme 0.831
0.94
1 month 0.83
Extreme 0.831
1.12
Current year 0.83
Extreme 0.831
1.44
1 year 0.83
Extreme 0.831
1.95
3 years 0.83
Extreme 0.831
19.62
5 years 0.83
Extreme 0.831
36.64
10 years 0.83
Extreme 0.831
43.92
Manager TitleAgeSince
Chief Executive Officer 60 2016-01-31
Director of Finance/CFO 49 2018-11-30
Chief Tech/Sci/R&D Officer 62 2026-09-29
Director TitleAgeSince
Director/Board Member 60 2016-01-31
Director/Board Member 74 2017-07-31
Chairman 56 2018-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26 Free

Chief Technology Officer

575,000 0.9286%
7/9/26 Free

Director

60,000 0.0969%
7/9/26 Free

Director

60,000 0.0969%
Change 5-day change 1-year change 3-year change Capi.($)
-0.20%-4.03%-52.29%-93.67% 53.48M
-2.54%+1.31%+54.27%+114.96% 1,135B
-1.42%+3.23%+38.56%+74.44% 635B
+0.16%+0.08%+25.29%+95.23% 505B
-0.31%+3.09%+44.14%+64.80% 378B
-1.34%-0.47%+66.04%+41.00% 358B
-0.68%+2.65%+22.98%+50.39% 295B
-1.20%+3.04%+2.33%+22.86% 266B
-1.79%+1.57%+50.56%+59.08% 237B
-0.73%-0.10%+29.02%+99.67% 193B
Average -1.01%+1.55%+28.09%+52.88% 400.37B
Weighted average by Cap. -1.35%+2.66%+41.02%+79.75%

Financials

2026 *2027 *
Net sales - -
Net income -88.99M -79.47M -73.42M -66.53M -124M -8.45B -127M -883M -350M -4.43B -334M -327M -13.95B -93.58M -83.57M -77.2M -69.96M -131M -8.88B -133M -929M -368M -4.65B -351M -344M -14.67B
Net Debt -118M -105M -97.38M -88.25M -165M -11.21B -168M -1.17B -464M -5.87B -443M -434M -18.51B -41.79M -37.32M -34.48M -31.25M -58.46M -3.97B -59.42M -415M -164M -2.08B -157M -154M -6.55B
Projected Income Statement - Annual - Pliant Therapeutics, Inc.
Logo Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
Employees
49
Date Price Change Volume
26-10-23 US$0.8636 -0.20% 446,817
26-10-22 US$0.8653 -2.31% 289,803
26-10-21 US$0.8858 -2.92% 340,621
26-10-20 US$0.9124 +1.52% 319,686
26-10-19 US$0.8987 -0.13% 292,307
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Pliant Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
0.8636USD
Average target price
2.000USD
Spread / Average Target
+131.59%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Pliant Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. PLRX Stock